TENAYA THERAPEUTICS INC. - COMMON STOCK

Tenaya Therapeutics Announces Proposed Public Offering

16 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

10 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022

04 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress

04 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions

29 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences

29 Sep 2022 06:45:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

06 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction

06 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

10 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure

06 Jul 2022 13:00:00 By Nasdaq GlobeNewswire